Control of aggressive 4T1-luc metastatic breast cancer using immunogenic cell lysates generated with methotrexate
Luana Cristina Camargo1, Pedro Burgel2, Camila Magalhães Cardador3
1Institute of Biological Sciences, University of Brasília, Brasília, Brazil; Department of Basic Psychological Processes, Institute of Psychology, University of Brasília, Brasília, Brazil.
Abstract:
This study investigated a novel immunization therapy for pre-clinical aggressive metastatic breast cancer using immunogenic cell lysates derived from 4T1-luc cells treated with cisplatin and methotrexate, addressing the critical need for improved treatments given the poor prognosis associated with breast cancer metastasis and its significant mortality rate. Methotrexate, a conventional cytotoxic agent, demonstrated a previously unrecognized capacity to induce immunogenic cell lysates, presenting a potential drug repositioning opportunity. In a murine model of stage IV metastatic breast cancer, immunization with these lysates significantly reduced primary tumor growth and lung metastasis, as assessed by bioluminescence imaging. Immunization also modulated immune cell populations, reducing splenomegaly and hepatomegaly, and partially reversing the immunosuppressive phenotype associated with 4T1-luc tumor growth, as evidenced by cytokine profiling (IL-6 and IFN-γ) and flow cytometry analysis of CD4 + and CD8 + T cell subpopulations. Specifically, methotrexate-treated lysates induced a significant shift in CD4 + T cells towards an effector phenotype. These findings highlight the potential of this immunotherapy approach to improve breast cancer treatment outcomes and warrant further investigation.
Insights
This study shows that immunogenic cell lysates from chemotherapy-treated breast cancer cells can be a novel immunotherapy. This approach reduced tumor growth and metastasis in mice, offering new hope for aggressive breast cancer treatment.
Area of Science:
- Oncology
- Immunology
- Cancer Therapy
Background:
- Breast cancer metastasis has a poor prognosis and high mortality rate, necessitating novel treatment strategies.
- Conventional cytotoxic agents like methotrexate may possess uncharacterized immunomodulatory properties.
- Developing effective immunotherapies is crucial for improving outcomes in aggressive metastatic breast cancer.
Purpose of the Study:
- To investigate a novel immunotherapy using immunogenic cell lysates from 4T1-luc breast cancer cells treated with cisplatin and methotrexate.
- To evaluate the efficacy of this novel immunization therapy in a pre-clinical model of aggressive metastatic breast cancer.
- To explore the immunomodulatory effects of methotrexate-treated cell lysates.
Main Methods:
- Generation of immunogenic cell lysates from 4T1-luc cells treated with cisplatin and methotrexate.
- Administration of these lysates as an immunization therapy in a murine model of stage IV metastatic breast cancer.
- Assessment of tumor growth and metastasis using bioluminescence imaging, and analysis of immune cell populations and cytokine profiles (IL-6, IFN-γ) via flow cytometry.
Main Results:
- Immunization with the novel lysates significantly reduced primary tumor growth and lung metastasis in the murine model.
- The therapy modulated immune cell populations, reducing splenomegaly and hepatomegaly.
- Methotrexate-treated lysates partially reversed the immunosuppressive tumor microenvironment and shifted CD4+ T cells towards an effector phenotype.
Conclusions:
- Immunogenic cell lysates derived from chemotherapy-treated breast cancer cells represent a promising novel immunotherapy.
- Methotrexate exhibits potential for drug repositioning as an agent to generate immunogenic cell lysates.
- This immunotherapy approach warrants further investigation for improving treatment outcomes in aggressive metastatic breast cancer.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...